BeiGene(BGNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BGNE BeiGene

Market Closed 12-20 16:00:00 EST

176.50

+1.78

+1.02%

盘后177.10

+0.60+0.34%

17:23 EST

High179.25	Low175.80	Vol368.34K
Open176.29	D1 Closing174.72	Amplitude1.97%
Mkt Cap18.75B	Tradable Cap11.27B	Total Shares106.25M
T/O65.24M	T/O Rate0.58%	Tradable Shares63.86M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"BGNE","market":"US","secType":"STK","nameCN":"BeiGene","latestPrice":176.5,"timestamp":1734728400000,"preClose":174.72,"halted":0,"volume":368336,"hourTrading":{"tag":"盘后","latestPrice":177.1,"preClose":176.5,"latestTime":"17:23 EST","volume":45232,"amount":7983522.32,"timestamp":1734733397830},"delay":0,"floatShares":63856225,"shares":106246194,"eps":-8.186614,"marketStatus":"Market Closed","change":1.78,"latestTime":"12-20 16:00:00 EST","open":176.29,"high":179.25,"low":175.8,"amount":65235476.97296,"amplitude":0.019746,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-8.186614,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1734944400000},"marketStatusCode":7,"adr":1,"adrRate":13,"exchange":"NASDAQ","adjPreClose":174.72,"preHourTrading":{"tag":"盘前","latestPrice":175.99,"preClose":174.72,"latestTime":"08:05 EST","volume":38,"amount":6640.4297,"timestamp":1734699902954},"postHourTrading":{"tag":"盘后","latestPrice":177.1,"preClose":176.5,"latestTime":"17:23 EST","volume":45232,"amount":7983522.32,"timestamp":1734733397830},"volumeRatio":0.8498489081134644,"impliedVol":0.4329,"impliedVolPercentile":0.4405},"requestUrl":"/m/hq/s/BGNE","defaultTab":"news","newsList":[{"id":"2492165236","title":"BeiGene gets FDA orphan designation in Waldenstrom macroglobulinemia treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2492165236","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492165236?lang=en_us&edition=fundamental","pubTime":"2024-12-19 07:00","pubTimestamp":1734562817,"startTime":"0","endTime":"0","summary":"BeiGene’s (BGNE) BTK-targeting chimeric degradation activation compound designed to degrade wildtype BTK and multiple mutant forms received FDA orp...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beigene-gets-fda-orphan-designation-in-waldenstrom-macroglobulinemia-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beigene-gets-fda-orphan-designation-in-waldenstrom-macroglobulinemia-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BGNE","BK4139","BK4505","BK4548","BK4535","BK4585","BK4504","BK4526"],"gpt_icon":0},{"id":"2492249859","title":"BeiGene’s Strategic Advancements and Promising Clinical Developments Justify Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2492249859","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492249859?lang=en_us&edition=fundamental","pubTime":"2024-12-18 13:36","pubTimestamp":1734500164,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Andrew Berens has maintained their bullish stance on BGNE stock, giving a Buy rating yesterday. Andrew Berens has given hi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/beigenes-strategic-advancements-and-promising-clinical-developments-justify-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/beigenes-strategic-advancements-and-promising-clinical-developments-justify-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BGNE"],"gpt_icon":0},{"id":"2492995477","title":"BeiGene’s Strategic Advancements and Promising Pipeline Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2492995477","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492995477?lang=en_us&edition=fundamental","pubTime":"2024-12-17 21:15","pubTimestamp":1734441315,"startTime":"0","endTime":"0","summary":"Jefferies analyst Kelly Shi assigned a Buy rating on BeiGene (BGNE – Research Report) today and set a price target of $286.00. Kelly Shi has given ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/beigenes-strategic-advancements-and-promising-pipeline-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/beigenes-strategic-advancements-and-promising-pipeline-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BGNE"],"gpt_icon":0},{"id":"2492956611","title":"BeiGene (BGNE) Gets a Buy from TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2492956611","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492956611?lang=en_us&edition=fundamental","pubTime":"2024-12-17 20:15","pubTimestamp":1734437736,"startTime":"0","endTime":"0","summary":"In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on BeiGene (BGNE – Research Report), with a price target of $260.00....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/beigene-bgne-gets-a-buy-from-td-cowen?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/beigene-bgne-gets-a-buy-from-td-cowen?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4504","BK4588","BK4548","BGNE","BK4535","TD","BK4139","BK4207","BK4127","COWN","BK4505","BK4585","BK4566","BK4526"],"gpt_icon":0},{"id":"2492995575","title":"BeiGene, Ltd.'s (NASDAQ:BGNE) recent 15% pullback adds to one-year year losses, institutional owners may take drastic measures","url":"https://stock-news.laohu8.com/highlight/detail?id=2492995575","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492995575?lang=en_us&edition=fundamental","pubTime":"2024-12-17 19:39","pubTimestamp":1734435591,"startTime":"0","endTime":"0","summary":"Key Insights Given the large stake in the stock by institutions, BeiGene's stock price might be vulnerable to their...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bgne/beigene/news/beigene-ltds-nasdaqbgne-recent-15-pullback-adds-to-one-year","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":[".IXIC","MNQmain","IE00BKPKM429.USD","IE00B3QW5Z07.USD","NDAQ","LU0588546209.SGD","LU1969619763.USD","TSYW.SI","BK4535","BGNE","BK4526","IE00B64PRP62.GBP","NVIW.SI","LU2210150020.SGD","LU2328871848.SGD","BK1161","SQQQ","BEIGF","BK4548","BK1500","BK1588","LU0307460666.USD","IE00BGHQF748.EUR","LU2210149790.SGD","TQQQ","BK4588","QID","PSQ","BK4585","QLD","06160","BK4139","BK4504","BK4505","NQmain","USJW.SI","BK4112","BK1583","USAW.SI","LU2095319765.USD"],"gpt_icon":1},{"id":"2492600575","title":"BeiGene: Promising Growth Trajectory and Investment Opportunity Backed by Strong Product Pipeline and Robust Financials","url":"https://stock-news.laohu8.com/highlight/detail?id=2492600575","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492600575?lang=en_us&edition=fundamental","pubTime":"2024-12-17 13:25","pubTimestamp":1734413119,"startTime":"0","endTime":"0","summary":"Analyst Reni Benjamin of JMP Securities reiterated a Buy rating on BeiGene (BGNE – Research Report), retaining the price target of $288.00. Reni Be...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/beigene-promising-growth-trajectory-and-investment-opportunity-backed-by-strong-product-pipeline-and-robust-financials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/beigene-promising-growth-trajectory-and-investment-opportunity-backed-by-strong-product-pipeline-and-robust-financials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4548","BK4526","BK4585","BK4139","BK4588","BK4535","BGNE","BK4505","BK4504"],"gpt_icon":0},{"id":"2491937312","title":"Sector Update: Health Care Stocks Steady Premarket Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2491937312","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491937312?lang=en_us&edition=fundamental","pubTime":"2024-12-13 22:17","pubTimestamp":1734099461,"startTime":"0","endTime":"0","summary":"Health care stocks were steady premarket Friday, with The Health Care Select Sector SPDR Fund  marginally higher and the iShares Biotechnology ETF  inactive.BeiGene  shares were up over 2% after the company said overnight it signed a global licensing deal with CSPC Zhongqi Pharmaceutical Technology for its experimental cancer therapy, SYH2039.Geron  stock was over 1% higher after the company said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of Rytelo for the treatment of adult patients with transfusion-dependent anemia due to lower risk myelodysplastic syndromes.Candel Therapeutics  shares were down past 33% after the company said overnight it priced an underwritten public offering of 10 million common shares at $6 apiece and pre-funded warrants to buy up to a total of 3.3 million shares of its common stock at $5.99 per warrant to raise about $80 million in gross proceeds.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4548","BK4139","BK4588","IBB","XLV","BK4539","BGNE","BK4535","BK4505","GERN","CADL","BK4581","BK4585","BK4504","BK4526"],"gpt_icon":1},{"id":"2491328125","title":"BeiGene Enters Global Licensing Agreement with CSPC Zhongqi for Experimental Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2491328125","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491328125?lang=en_us&edition=fundamental","pubTime":"2024-12-13 18:54","pubTimestamp":1734087274,"startTime":"0","endTime":"0","summary":"BeiGene  said late Thursday it has signed a global licensing agreement with CSPC Zhongqi Pharmaceutical Technology for its experimental cancer therapy, SYH2039.Under the terms of the deal, the company said it has an exclusive worldwide license to develop, manufacture and commercialize SYH2039.CSPC will receive $150 million in upfront, time-based payments, potential milestone payments and tiered royalties.The company said its experimental drug, BGB-58067, is expected to enter clinical trials by the end of the year and aims to avoid the hematological toxicity associated with first-generation PRMT5 inhibitors.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4535","BK1588","BK4588","BK4139","BK4548","06160","BK4585","LU0307460666.USD","BK4526","LU0588546209.SGD","LU2328871848.SGD","LU1969619763.USD","BK1500","BK1583","BGNE","BK4505","BK1161","BK4504"],"gpt_icon":0},{"id":"2491442733","title":"CSPC Pharmaceutical Group Grants Exclusive License of Cancer Inhibitor to BeiGene Switzerland","url":"https://stock-news.laohu8.com/highlight/detail?id=2491442733","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491442733?lang=en_us&edition=fundamental","pubTime":"2024-12-13 17:48","pubTimestamp":1734083293,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group (HKG:1093) agreed to grant an exclusive license for the development, manufacturing, and commercialization of a cancer inhibitor (SYH2039) to BeiGene Switzerland, a Friday Hon","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1191","BK1161","LU1008478684.HKD","IE00BZ08YS42.EUR","LU1226288253.USD","LU1226288170.HKD","SG9999004220.SGD","BK4548","LU0140636845.USD","LU0072913022.USD","LU0307460666.USD","IE00BZ08YR35.GBP","IE00B543WZ88.USD","LU1960683339.HKD","BK4526","IE00B031HY20.USD","BK4585","LU1152091168.USD","IE0008368742.USD","BK4505","LU0880133367.SGD","BK1583","LU1951186391.HKD","BK1515","LU1226287875.USD","LU1969619763.USD","IE00B5MMRT66.SGD","BK1588","LU0067412154.USD","BK4588","LU2328871848.SGD","06160","IE0008369823.USD","LU0501845795.SGD","LU1152091754.HKD","BK1500","LU0326950275.SGD","LU0588546209.SGD","IE00BZ08YT58.USD","BK4535","BGNE","LU1226287529.USD","LU1226287792.SGD","LU1993786604.SGD","01093","LU1807302812.USD","BK4504","BK1521","BK4139"],"gpt_icon":0},{"id":"2491367819","title":"CSPC Pharmaceutical Partners with BeiGene on Innovative Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2491367819","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491367819?lang=en_us&edition=fundamental","pubTime":"2024-12-13 08:38","pubTimestamp":1734050309,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group (HK:1093) has released an update. CSPC Pharmaceutical Group has entered into an exclusive license agreement with BeiGene ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cspc-pharmaceutical-partners-with-beigene-on-innovative-cancer-drug?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cspc-pharmaceutical-partners-with-beigene-on-innovative-cancer-drug?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4504","BK4505","BK4535","BGNE","BK4548","BK4139","BK4526","BK4585","BK4588"],"gpt_icon":0},{"id":"2491936789","title":"BeiGene announces global licensing agreement for MAT2A inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2491936789","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491936789?lang=en_us&edition=fundamental","pubTime":"2024-12-13 08:35","pubTimestamp":1734050107,"startTime":"0","endTime":"0","summary":"BeiGene (BGNE) announced it has entered into a global licensing agreement with CSPC Zhongqi Pharmaceutical Technology Co., Ltd. for SYH2039, a nove...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beigene-announces-global-licensing-agreement-for-mat2a-inhibitor?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beigene-announces-global-licensing-agreement-for-mat2a-inhibitor?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","BK4585","BK4526","BGNE","BK4548","BK4504","BK4139","BK4505","BK4588"],"gpt_icon":0},{"id":"2491401362","title":"BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2491401362","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491401362?lang=en_us&edition=fundamental","pubTime":"2024-12-13 08:30","pubTimestamp":1734049800,"startTime":"0","endTime":"0","summary":"SYH2039 targets solid tumors that have a mutation called MTAP deletion, which is estimated to be present in approximately 15 percent of all cancer types with the most common including glioblastoma, pancreatic cancer and non-small cell lung cancer.BeiGene, which plans to change its name to BeOne Medicines, is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of nearly 11,000 colleagues spans five continents. To learn more about BeiGene, please vi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/7TQ0awq6gFoiAfZfEaYbqA--~B/aD0zMTA7dz0xNjUwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/0a65303e38c80893a4e8441d930bbbc5","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/7TQ0awq6gFoiAfZfEaYbqA--~B/aD0zMTA7dz0xNjUwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/0a65303e38c80893a4e8441d930bbbc5"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beigene-announces-global-licensing-agreement-003000673.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4139","BK4504","BK4548","PHH","BK4585","BK4505","BGNE","BK4535","WRD","BK4526"],"gpt_icon":0},{"id":"2490863702","title":"BeiGene’s Strong Pipeline and Financial Position Make It a Compelling Buy Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2490863702","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490863702?lang=en_us&edition=fundamental","pubTime":"2024-12-11 22:55","pubTimestamp":1733928915,"startTime":"0","endTime":"0","summary":"In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on BeiGene (BGNE – Research Report), with a price target of $...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/beigenes-strong-pipeline-and-financial-position-make-it-a-compelling-buy-opportunity?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/beigenes-strong-pipeline-and-financial-position-make-it-a-compelling-buy-opportunity?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4585","BK4505","BK4588","BK4548","BK4526","BGNE","BK4535","BK4504"],"gpt_icon":0},{"id":"2490855056","title":"BeiGene Secures $400 Million Facility from China Merchants Bank","url":"https://stock-news.laohu8.com/highlight/detail?id=2490855056","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490855056?lang=en_us&edition=fundamental","pubTime":"2024-12-11 20:21","pubTimestamp":1733919684,"startTime":"0","endTime":"0","summary":"BeiGene  entered into a $400 million facility agreement with China Merchants Bank  on Tuesday, a same-day filing with the Hong Kong Exchange said.The facility agreement will provide the company with an uncommitted and unsecured credit facility where each loan will have a term of up to one whole year while the overall term for the total loan is set at 18 months from the signing date.The company plans to use the borrowing for refinancing its working capital loans with other banks and for the group's daily operations.The company entered a similar facility agreement with the bank in 2023. The agreement will terminate in January 2025. Out of the $400 million facility, $380 million was withdrawn by the company, which plans to pay back $300 million this month, the filing said.The $80 million remaining from the previous facility agreement will be counted toward the availability under the new facility agreement.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BGNE","LU0348827113.USD","688235","LU1969619763.USD","LU0287142896.SGD","LU2097828714.EUR","LU0979878070.USD","BK1610","LU0797268264.HKD","LU0588546209.SGD","BK4526","LU1064131003.USD","LU0516423091.SGD","LU0327786744.USD","LU1720050803.USD","BK4585","LU1224709979.USD","LU1242518931.SGD","LU2289578879.USD","LU2226246903.HKD","IE00B031HY20.USD","LU0488056044.USD","BK1560","LU1105468828.SGD","LU0320764599.SGD","LU0229945570.USD","LU1997245177.USD","IE00BVYPNQ40.USD","LU2097828557.USD","LU0029874905.USD","IE0008368742.USD","IE00B543WZ88.USD","BK1507","03143","LU0516423174.USD","LU0348788117.USD","LU0890818403.SGD","LU1282649067.USD","LU1997244956.HKD","LU1960683339.HKD","600036","BK0278","BK0012","LU0455707207.USD","LU2476274308.USD","06160","IE00BGHQDM52.EUR","03968","LU1820825898.SGD","LU0244354667.USD"],"gpt_icon":0},{"id":"2490801798","title":"Asian Equities Traded in the US as American Depositary Receipts Sharply Lower in Tuesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2490801798","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490801798?lang=en_us&edition=fundamental","pubTime":"2024-12-10 23:47","pubTimestamp":1733845673,"startTime":"0","endTime":"0","summary":"Asian equities traded in the US as American depositary receipts were sharply lower Tuesday morning, falling 1.4% to 2,107.41 on the S&P Asia 50 ADR Index.From North Asia, the gainers were led by utilities company Korea Electric Power  and semiconductor company Himax Technologies , which rose 1.6% and 0.9% respectively. They were followed by thin-film liquid display maker LG Display  and pet-focused platform Boqii , which were up 0.5% and 0.2% respectively.The decliners from North Asia were led by online brokerage UP Fintech  and video-sharing platform Bilibili , which fell 11% and 9.8%  respectively. They were followed by brand platform 36Kr  and oncology company BeiGene , which dropped 9% and 8.9% respectively.From South Asia, the gainers were led by IT firm Wipro , which rose 1%, followed by telecommunications operator Telekomunikasi Indonesia  and financial services company ICICI Bank , which increased 0.5% and 0.2% respectively.The decliners from South Asia were led by pharmaceutic","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"5904cec092f61b0cc51b4500f11c9ff5","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HIMX","LU1481012133.USD","BK4107","PHI","IE00B7N09G41.SGD","SG9999004220.SGD","LU0143863784.USD","RDY","LU1868837565.USD","BK4526","BK4585","LU1102505929.USD","SIFY","KEP","RDY.AU","BK4505","BK4132","BQ","BK4523","BK4513","BK4554","WIT","BILI","KRKR","LU0348744763.USD","BK4518","LU0531971678.HKD","LU0261950470.USD","LU0541501648.USD","LU0143863198.USD","BK4566","LU0251143458.SGD","BK4085","AFG","LU0828237940.HKD","IBN","BGNE","BK4531","LU1102505762.USD","TIGR","BK4127","LU1868837722.USD","LPL","TLK","NQGM","LU1868838027.USD","LU0048575426.USD","BK4134","LU0823038988.USD","BK4139"],"gpt_icon":1},{"id":"1183254431","title":"Stock Track | BeiGene Stock Plummets 5.83% on Tuesday, Recovery Expected in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1183254431","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183254431?lang=en_us&edition=fundamental","pubTime":"2024-12-10 22:34","pubTimestamp":1733841298,"startTime":"0","endTime":"0","summary":"BeiGene, a Chinese biopharmaceutical company, saw its stock  plummet by 5.83% on Tuesday during the intraday trading session.Despite the plunge, analysts at Deutsche Bank believe that the recovery momentum seen in China's healthcare companies, including BeiGene, since mid-August is expected to continue in 2025. This recovery is anticipated to be driven by the following factors:. The Chinese government's supportive policy on innovative drugs and pricing. According to Cyrus Ng, an analyst at Deuts","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Stock Track | BeiGene Stock Plummets 5.83% on Tuesday, Recovery Expected in 2025","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["BGNE"],"gpt_icon":0},{"id":"2490030334","title":"China Healthcare Sector's Recovery Momentum May Continue in 2025 -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2490030334","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490030334?lang=en_us&edition=fundamental","pubTime":"2024-12-10 10:50","pubTimestamp":1733799000,"startTime":"0","endTime":"0","summary":"0250 GMT - The recovery momentum seen in China's healthcare companies since mid-August is expected to continue in 2025, says Cyrus Ng, an analyst at Deutsche Bank. The recovery should be helped by the Chinese government's supportive policy on innovative drugs and pricing, and an expected improvement in biotech funding, he says in a note. China's healthcare stocks have lagged behind the Hang Seng Index in 2024 amid geopolitical tensions and a difficult biotech funding environment, he notes. However, with improvement in sentiment and the government's supportive measures, China's biotech funding is expected to start recovering gradually in 2025, he says. Ng's sector picks include Beigene, Hansoh and CSPC. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1226287529.USD","LU1226287875.USD","IE00BZ08YR35.GBP","LU1951186391.HKD","BK4137","IE00B543WZ88.USD","IE0008368742.USD","LU1152091754.HKD","LU1226288170.HKD","BK4505","LU0326950275.SGD","LU0067412154.USD","LU0140636845.USD","LU0501845795.SGD","IE00B031HY20.USD","BK1515","BK4504","BK4585","LU1960683339.HKD","LU0880133367.SGD","LU1993786604.SGD","03692","BGNE","IE00BZ08YS42.EUR","LU0072913022.USD","IE0008369823.USD","HCSG","BK1191","LU1226287792.SGD","01093","LU1008478684.HKD","BK4535","BK4139","SG9999004220.SGD","BK4526","LU1226288253.USD","BK4588","BK1583","BK1589","IE00BZ08YT58.USD","LU1152091168.USD","BK4548","IE00B5MMRT66.SGD","BK1521","LU1807302812.USD"],"gpt_icon":0},{"id":"2490603952","title":"BeiGene discloses new data in BRUKINSA, promising advancements pipeline at ASH","url":"https://stock-news.laohu8.com/highlight/detail?id=2490603952","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490603952?lang=en_us&edition=fundamental","pubTime":"2024-12-10 09:35","pubTimestamp":1733794543,"startTime":"0","endTime":"0","summary":"BeiGene (BGNE) “announced the presentation of new clinical data at the 66th American Society of Hematology Annual Meeting and Exposition, underscor...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beigene-discloses-new-data-in-brukinsa-promising-advancements-pipeline-at-ash?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beigene-discloses-new-data-in-brukinsa-promising-advancements-pipeline-at-ash?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ASH","BK4585","BK4535","BK4526","BK4588","BGNE","BK4548","LU2463526074.USD","BK4505","BK4109","BK4504"],"gpt_icon":0},{"id":"2490034520","title":"BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2490034520","media":"Business Wire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490034520?lang=en_us&edition=fundamental","pubTime":"2024-12-10 09:30","pubTimestamp":1733794200,"startTime":"0","endTime":"0","summary":"At a median follow-up of 1.5 years, promising data from the 320 mg expansion cohort of phase 1/1b study shows no progression in patients with treatment-nave CLL treated with sonrotoclax, a next-generation BCL2 inhibitor, in combination with BRUKINSA highlighting the potential of this fixed-duration, oral-only combination as a best-in-disease option. Data for BTK degrader BGB-16673 from phase 1/2 study highlight its potential in both treatment-resistant CLL and other B-cell malignancies representing high unmet needs. Long-term follow-up results from the ongoing Phase 3 SEQUOIA study presented during ASH, which were simultaneously published in the Journal of Clinical Oncology, reaffirm BRUKINSA’s durable efficacy and differentiated safety profile across diverse CLL patient populations, including those with high-risk features. Additional findings spotlight the promising potential of BeiGene’s BTK-targeted chimeric degradation activation compound , BGB-16673, which has shown rapid and deep","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/comeQUB3l.hqpFxOkwB50A--~B/aD0zMTA7dz0xNjUwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/8552ade3798910105084d5d0d62e0d93","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/comeQUB3l.hqpFxOkwB50A--~B/aD0zMTA7dz0xNjUwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/8552ade3798910105084d5d0d62e0d93"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beigene-advances-leadership-cll-ash-013000068.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4566","LU0472753341.HKD","TLS","LU2041044095.USD","LU0689626769.HKD","WM","BK4505","LU0511384066.AUD","BK4533","LU2463526074.USD","BK4588","BK4109","LU2211814178.USD","FL","LU1923621640.USD","IE0034235188.USD","LU2092937221.SGD","LU2238339852.HKD","BR","LU2362541513.USD","LU0069063385.USD","BK4535","BK4585","LU1892829315.USD","LU1939255532.USD","LU2106854487.HKD","LU1974910355.USD","PHH","LU1430594728.SGD","LU2298064838.USD","WRD","LU2355687059.USD","LU1721428933.USD","LU0057025933.USD","LU1228905540.USD","BK4139","ASH","IE0009354923.USD","LU1585245621.USD","LU0347712357.USD","LU2362541273.HKD","LU1228905037.USD","LU2125910179.SGD","BK4106","BK4097","BGNE","LU1917777945.USD","LU0124676726.USD","LU0390134368.USD","LU2229751404.USD"],"gpt_icon":0},{"id":"2488167969","title":"BeiGene Ltd Announces New Share Options and RSUs","url":"https://stock-news.laohu8.com/highlight/detail?id=2488167969","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488167969?lang=en_us&edition=fundamental","pubTime":"2024-12-04 20:10","pubTimestamp":1733314214,"startTime":"0","endTime":"0","summary":"BeiGene Ltd (HK:6160) has released an update. BeiGene Ltd has granted 5,227 share options and 50,248 restricted share units (RSUs) under its 2016 S...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/beigene-ltd-announces-new-share-options-and-rsus?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/beigene-ltd-announces-new-share-options-and-rsus?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BGNE","BK4526","BK4585","BK4139","BK4535","BK4505","BK4548","BK4588","BK4504"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beigene.cn","stockEarnings":[{"period":"1week","weight":-0.0159},{"period":"1month","weight":-0.0914},{"period":"3month","weight":-0.1262},{"period":"6month","weight":0.1306},{"period":"1year","weight":-0.0033},{"period":"ytd","weight":-0.0214}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.062331},{"month":2,"riseRate":0.625,"avgChangeRate":0.017001},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.028933},{"month":4,"riseRate":0.444444,"avgChangeRate":0.028699},{"month":5,"riseRate":0.444444,"avgChangeRate":-0.01513},{"month":6,"riseRate":0.555556,"avgChangeRate":0.015441},{"month":7,"riseRate":0.777778,"avgChangeRate":0.136456},{"month":8,"riseRate":0.555556,"avgChangeRate":0.036185},{"month":9,"riseRate":0.555556,"avgChangeRate":0.064683},{"month":10,"riseRate":0.555556,"avgChangeRate":0.004837},{"month":11,"riseRate":0.555556,"avgChangeRate":0.060012},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.040753}],"exchange":"NASDAQ","name":"BeiGene","nameEN":"BeiGene"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BeiGene(BGNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BeiGene(BGNE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BeiGene,BGNE,BeiGene股票,BeiGene股票老虎,BeiGene股票老虎国际,BeiGene行情,BeiGene股票行情,BeiGene股价,BeiGene股市,BeiGene股票价格,BeiGene股票交易,BeiGene股票购买,BeiGene股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BeiGene(BGNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BeiGene(BGNE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}